Introduction {#sec0005}
============

*G. sanguinis* was described in 1992 as a new genus and species of catalase-negative, facultatively anaerobic, non-motile, non-hemolytic, Gram-positive cocci (GPC) forming short chains or pairs by Collins, et al. [@bib0005]. Only 42 isolates from clinical specimens and 13 case reports about UTI, bacteremia, or meningitis have been reported ([Table 1](#tbl0005){ref-type="table"}). These reports suggest that *G. sanguinis* can colonize inguinal skin [@bib0010] and aged female patients with a history of cerebrovascular disease are susceptible to *G. sanguinis*. However, the epidemiology and the clinical significance of this pathogen remain largely unknown. *G. sanguinis* is an unusual pathogen that it could be misidentified or misdiagnosed with viridans streptococci (or may be overlooked) due to its colonial morphology [@bib0015]. We successfully identified the organism using the Rapid ID32 Strep system. We present the first case of an infective endocarditis by *G. sanguinis* following a UTI.Table 1Clinical reported 42 cases of *G. sanguinis* infections.Table 1ReferenceCountryAgeGenderUnderlying conditionsPresenting signs and symptomsSite of isolationInfectionIdentificationAntibiotic treatmentOutcome[@bib0010]France56FN/AmeningitisCSFmeningitis16S rRNA sequencingCTX, FOMalive[@bib0015]USAN/AFN/AN/AbloodbacteremiaRapid ID 32 Strep + BBL Crystal Rapid Gram-Positive ID kit + BBL Crystal Gram-Positive ID kit + RapID STRN/AN/A[@bib0015]USAN/AFN/AN/Abloodbacteremiasame as aboveN/AN/A[@bib0015]USAN/AMN/AN/Aurineurinarysame as aboveN/AN/A[@bib0015]USAN/AN/AN/AN/Abloodbacteremiasame as aboveN/AN/A[@bib0015]USAN/AN/AN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA69MN/AN/Aurineurinarysame as aboveN/AN/A[@bib0015]USA85FN/AN/Aurineurinarysame as aboveN/AN/A[@bib0015]USAN/AN/AN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA1MN/AN/ACSFmeningitissame as aboveN/AN/A[@bib0015]USA84FN/AN/Abloodsepsissame as aboveN/AN/A[@bib0015]canadaN/AFN/AN/AurineN/Asame as aboveN/AN/A[@bib0015]USA90FN/AN/Abloodurosepsissame as aboveN/AN/A[@bib0015]USA68FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]canada82FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]canada79FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USAN/AN/AN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA1MN/AN/Abloodseptocemiasame as aboveN/AN/A[@bib0015]USAN/AN/AN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA58MN/AN/Abloodseptocemiasame as aboveN/AN/A[@bib0015]USA82FN/AN/Abloodseptocemiasame as aboveN/AN/A[@bib0015]canada2FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]canada92FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]canadaN/AFN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA70FN/AN/Abloodendocarditissame as aboveN/AN/A[@bib0015]canada43FN/AN/ACSFN/Asame as aboveN/AN/A[@bib0015]canada85MN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]canada1FN/AN/AbloodN/Asame as aboveN/AN/A[@bib0015]USA3FN/AN/Abloodsepticemiasame as aboveN/AN/A[@bib0020]Japan80Fcolon cancer, brain stroke,dementia, HTNfever, pyuriaurineurinary16S rRNA sequencingABPCalive[@bib0025]Korea85Fparkinson\'s disease, asthma, hypertwnsion, staying at nursing homepain and swelling of left arm, feverbloodbacteremiapartial 16S rRNA sequencingVCM + CTRXalive[@bib0035]USA72Fobesity, gastrip lap banding, tabaccoHip painHip synoviumprosthetic joint infectionAPI 20TREP + Vitek 2 g-Positive ID card + MALDI-TOF MSVCMalive[@bib0035]USA54Fobesity, DM, gastric bypass, tabaccofatigue and feverbloodbacteremiaMALDI-TOF MSLZDalive[@bib0060]Taiwan80Fchronic diarrhea, DMcardiac arrestbloodbacteremia16S rRNA sequencingN/Adied[@bib0060]Taiwan92Fdementia, CHFfever, coughbloodurosepsis16S rRNA sequencingCXM = \> CAZalive[@bib0065]Denmark23Fintravenous drug use. Right-sided endocarditis, hepatitis CpneumoniabloodbacteremiaRapid ID32 Strep, partial 16S rRNA sequencingCXM = \> PCalive[@bib0065]Denmark82Falzheimer\'s disease, hypertensiondehydrationbloodurosepsisRapid ID32 Strep, partial 16S rRNA sequencingPCalive[@bib0065]Denmark56Mcrohn\'s disease, atrial fibrillationerysipelas, dyspnoea, feverbloodbacteremiaRapid ID32 Strep, partial 16S rRNA sequencingCXMalive[@bib0070]Japan94Mdementia, CHF, nephrolithiasisback pain, feverbloodbacteremia16S rRNA sequencingABPC/SBT = \> VCMalive[@bib0075]Germany69FVPSmeningitisCSFmeningitisRapid ID32 Strep, phoenix PMIC/ID-56CTRXalive[@bib0080]India70MCraniectomymeningitisCSFmeningitisVitek 2 IDLVFX, CPZ, SBT, AMK = \> VCM, LVFXalive[^2]

Case report {#sec0010}
===========

An 87 year-old Japanese woman was admitted to our hospital with recurrent episode of UTI, with a fever higher than 38.5 °C for 5 days, and with hematuria despite taking oral levofloxacin 500 mg and acetaminophen 1200 mg daily. She had been bedridden at nursing home since a subarachnoid hemorrhage and surgical construction of ventriculo-peritoneal shunt, and she had gastrostomy 10 years ago. On examination, she had body temperature of 36.5 °C, blood pressure 92/35 mmHg, pulse 84 bpm, respiratory rate 16 breaths/min, and pulse oxygen saturation 98% on room air. Physical examination showed Glasgow Coma Scale (GCS) of 7 (E2, V2, M3), inner lip bleeding, and systolic murmur at cardiac apex. Laboratory data at the admission was leucocyte count 35,600/mL, hemoglobin level 10.7 g/dL, platelet count 4.3000/mL, C-reactive protein 21.1 mg/dL, procalcitonin level 20.5 ng/mL, albumin 1.9 mg/dL, blood urea nitrogen 212 mg/dL, creatinine 3.9 ng/mL, uric acid 11.1 mg/dL, and lactate dehydrogenase 299 IU/L. Urine microscopy showed the presence of leukocytosis and numerous bacteria. Abdominal CT scans revealed bilateral hydronephrosis and hydroureters besides distended urinary bladder. After inserting urinary bladder catheter, pyuria and hematuria were obtained. Urinary gram stain showed GPC (1 + ) in pairs and short chains and Gram negative rods (GNR) (2+). She was diagnosed with infected hydronephrosis due to neurogenic bladder and started to receive ceftriaxone (CTRX) 2 g every 24 h empirically.

On day 3, her blood cultures from admission were growing aerobic, a-hemolytic GPC in short chains in 2 of 4 bottles ([Fig. 1](#fig0005){ref-type="fig"}A, B). On day 4, the isolates were identified as *G. sanguinis* with a high certainty (98.8%) by Rapid ID32 Strep (bioMerieux, Lyon, France). In order to double-check the results, we performed 16S rRNA sequencing because the species is rare and for confirmation of the diagnosis. Extended-spectrum b-lactamase producing *Escherichia coli* (ESBL-producing *E. coli*) simultaneously was observed in the two sets of blood culture bottles. *G. sanguinis* and ESBL-producing *E.coli* in her urine culture were also identified. She was diagnosed with bacteremia due to UTI caused by both of the organisms. The antimicrobial treatment was altered to meropenem 0.5 g every 12 h, for a 14-day course, considering antimicrobial susceptibility testing results ([Table 2](#tbl0010){ref-type="table"}) by WalkAway 40 SI system (Beckman Coulter, California, USA) and her renal function test results. Urine culture obtained before treating with meropenem showed the growth of *G. sanguinis* again, but her repeated blood and urine cultures after treatment were negative.Fig. 1(A) Microscopic appearance of the isolates from her blood after Gram staining (×1000). (B) morphology of colonies on sheep blood agar.Fig. 1Table 2Susceptibility Testing Results of *G. sanguinis*.Table 2MIC mg/mLInterpretationAMPC/CVA\< = 0.25\*ABPC\< = 0.06SAZM\< = 0.25SCDTR-PI1\*CFPM1SCTX2ICTM\>4\*CTRX2ICZOP1SCP\< = 4SCLDM\< = 0.12SEM\< = 0.12SLVFX8RMEPM0.25SMINO\< = 0.5SPCG0.06SST\>4\*VCM0.25S

On day 6 of the treatment with meropenem, transthoracic echocardiography revealed a 3 mm (in diameter) vegetation ([Fig. 2](#fig0010){ref-type="fig"}A) on the mitral valve besides mild aortic, mitral and tricuspid regurgitation. Meeting with Duke's criteria (1 major and 3 minor criteria), she was eventually diagnosed with IE due to UTI-associated bacteremia. Her CT scans showed there was no abscess formation on the entire body. On day 10 of meropenem, a 2 mm vegetation on left coronary cusp of aortic valve was discovered by transesophageal echocardiography (TEE) ([Fig. 2](#fig0010){ref-type="fig"}B). We presumed that *G. sanguinis* caused the endocarditis and administered her a 2 week of ampicillin 2 g every 8 h intravenously after completion of the meropenem treatment. After the 2 weeks of ampicillin, no vegetation was detected on TEE. She showed improvement and was discharged from the hospital to a nursing facility. She was in the hospital for 40 days.Fig. 2(A) Parasternal long axis view on transthoracic echocardiogram shows a vegetation on posterior leaflet of mitral valve (arrow). (B) Parasternal long axis view on transesophageal echocardiogram shows a vegetation on left coronary cusp of aortic valve (arrow).Fig. 2

Discussion {#sec0015}
==========

We believe that this is the first case of having IE followed with UTI caused *G. sanguinis* complicated with ESBL-producing *E.coli* infection. *G. sanguinis* looks like viridans streptococci in Gram-stain morphology and colonial morphology including hemolysis pattern on sheep blood agar but has difference in not producing leucine aminopeptidase (LAP) and growth in the presence of 6.5% NaCl. Susceptibility to the third-generation cephalosporins is also different: *G. sanguinis* is resistant while a-streptococcus is susceptible [@bib0015]. Although we successfully identified *G. sanguinis* by rapid ID32 Strep with a high certainty (98.8%), there are some past cases that failed *G. sanguinis* identification by the same methods [@bib0020]. There may be two reasons; one is that *G. sanguinis* shows various biochemical reaction depending on strain [@bib0025] and the other is that the data of *G. sanguinis* had not been collected on the database of the rapid ID32 Strep system until 2006. If rapid ID32 Strep fails to identify *G. sanguinis,* 16S rRNA sequencing is required. We additionally attempted Bruker matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bremen, Germany) with MBT Compass software using MALDI Biotyper library version 5.0. The identification process suggested not *G. sanguinis* but *G. sulfidifaciens* with cutoff score of 1.97 ([Table 3](#tbl0015){ref-type="table"}). *G. sulfidifaciens,* first described in 2001 isolated only from animals, has 99.2% similarity in 16S rRNA gene sequencing to *G. sanguinis* [@bib0030] but is different in biochemical reaction. Although, Miller et al. succeeded to identify *G. sanguinis* with Bruker MALDI-TOF MS with MBT 6903 MSP library database [@bib0035], MALDI-TOF MS is not so useful to identify the organism because there are only 3 *G. sanguinis* strains appeared in the database. An update of the database is needed.Table 3Results of Bruker MALDI-TOF MS analysis.Table 3Rank (Quality)Matched PatternScore value1 (+)Globicatella sulfidifaciens 11\_ 0100356_001_01 LGL1.972 (-)Stenotrophomonas maltophilia 10942 CHB1.443 (-)Pseudomonas boreopolis LMG 979T HAM1.394 (-)Stenotrophomonas sp 109_Neb28 NFI1.375 (-)Lactobacillus pentosus DSM 16366 DSM1.33

In our case, both *G. sanguinis* and *E. coli* were found in blood culture when the patient was admitted. IE caused by *E. coli* is rare (\<1%) and *G. sanguinis* has been reported to be an opportunistic pathogen [@bib0040], [@bib0045], [@bib0050]. Patients diagnosed with E.colli IE are reported to be often diabetic with underlying heart disease or have prosthetic valves. Surgery is often necessary and the mortality rate is high (17%) [@bib0055]. Therefore, we speculated that IE caused by *G. sanguinis* followed a subacute clinical course, similar to viridans streptococcus, and her IE was caused by *G. sanguinis*. In order to verify our speculation, identifying *G. sanguinis* IE correctly with Rapid ID 32 Strep, collecting more cases of *G. sanguinis* IE, and then revealing clinical feature of *G. sanguinis* IE are required.
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